A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 Jan 2018 Planned End Date changed from 20 Mar 2018 to 29 Mar 2019.
- 24 Jan 2018 Planned primary completion date changed from 20 Mar 2018 to 1 Mar 2018.
- 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.